Boehringer Ingelheim launches €100m corporate venture fund
Pharmaceuticals giant Boehringer Ingelheim has launched the Boehringer Ingelheim Venture Fund, a тЌ100m corporate venture vehicle.
The fund will invest in biotechnology companies and start-ups that have developed new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and/or first-in-class lead compounds. Disease-related biomarkers might be an additional area of focus.
First investments will be made in 2010 with a world-wide focus.
More on DACH
Dataciders sponsor Auctus mulls sale via Houlihan Lokey
German GP first acquired the local IT services group in May 2019 via Auctus V, a 2019-vintage
Bregal eyes local deal origination with new Swiss office
GP's third fund is completing its investment period, with fourth fund registered
Newly launched Utopia Capital aims to deploy EUR 10m-plus by 2028
Angel investor Christian Schroeder's new investment vehicle will support early-stage tech companies addressing humanitarian issues
Germany's DFL to collect NBOs for EUR 3bn media rights stake
Large-cap sponsors including Advent, Blackstone, Bridgepoint, CVC, EQT and KKR expected to bid today
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds